TNF and psoriasis: Infliximab (Remicade), approved for psoriasis in September 2005, is a chimeric monoclonal antibody that is part of the family of TNF-α antagonists (increased affinity and specificity for TNF-α) with cytotoxic, inhibiting and neutralizing action in psoriasis and other inflammatory diseases which are based on the hyperproduction of TNF.